Co-Authors
This is a "connection" page, showing publications co-authored by Luca Richeldi and Athol Wells.
Connection Strength
0.803
-
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med. 2018 02; 6(2):138-153.
Score: 0.185
-
Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017 Oct 20; 3:17074.
Score: 0.185
-
The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiology. 2020 07; 296(1):172-180.
Score: 0.055
-
The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic: A Multinational Consensus Statement From the Fleischner Society. Chest. 2020 07; 158(1):106-116.
Score: 0.055
-
Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis. Am J Respir Crit Care Med. 2019 01 01; 199(1):12-21.
Score: 0.050
-
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018 11 01; 379(18):1722-1731.
Score: 0.049
-
Validation of multidisciplinary diagnosis in IPF. Lancet Respir Med. 2018 02; 6(2):88-89.
Score: 0.047
-
A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. Am J Respir Crit Care Med. 2017 Nov 15; 196(10):1249-1254.
Score: 0.046
-
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res. 2017; 4(1):e000212.
Score: 0.046
-
Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? Lancet Respir Med. 2017 07; 5(7):591-598.
Score: 0.045
-
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015 Jul 15; 192(2):e3-19.
Score: 0.039